Abstract | Juvenile idiopathic arthritis (JIA) refers to a group of chronic childhood arthropathies of unknown etiology, currently classified into subtypes primarily on the basis of clinical features. Research has focused on the hypothesis that these subtypes arise through distinct etiologic pathways. In this Review, we discuss four subtypes of JIA: persistent oligoarticular, extended oligoarticular, rheumatoid-factor-positive polyarticular and rheumatoid-factor-negative polyarticular. These subtypes differ in prevalence between ethnic groups and are associated with different HLA alleles. Non-HLA genetic risk factors have also been identified, some of which reveal further molecular differences between these subtypes, while others suggest mechanistic overlap. Investigations of immunophenotypes also provide insights into subtype differences: adaptive immunity seems to have a prominent role in both polyarticular and oligoarticular JIA, and the more-limited arthritis observed in persistent oligoarticular JIA as compared with extended oligoarticular JIA may reflect more-potent immunoregulatory T-cell activity in the former. Tumor necrosis factor seems to be a key mediator of both polyarticular and oligoarticular JIA, especially in the extended oligoarticular subtype, although elevated levels of other cytokines are also observed. Limited data on monocytes, dendritic cells, B cells, natural killer T cells and neutrophils suggest that the contributions of these cells differ across subtypes of JIA. Within each subtype, however, common pathways seem to drive joint damage.
Introduction
Juvenile idiopathic arthritis (JIA) is a term that collectively refers to a group of chronic childhood arthro pathies, which together constitute the most common rheumatic condition in children. The latest (2001) International League of Associations for Rheumatology (ILAR) criteria define seven subtypes of JIA: systemic JIA (sJIA), oligoarticular JIA, rheumatoid factor (RF)-negative (RF -) polyarticular JIA, RF-positive (RF + ) polyarticular JIA, enthesitis-related arthritis (ERA), psori atic arthritis and undifferentiated JIA. 1 The ILAR classification includes persistent and extended oligo arthritis as sub categories of oligo articular JIA, but not as distinct subtypes. However, discussion regarding the robustness of this classification scheme continues. [2] [3] [4] [5] This Review focuses on developments regarding the epidemiology, genetics and immunopathogenesis of the oligoarticular and polyarticular subtypes. Progress in the understanding of sJIA, which seems to be an auto inflammatory rather than an autoimmune disease, 6 and of ERA, which is a clinically welldefined subtype typically associated with HLA-B27, 7 while of interest, are beyond the scope of this discussion.
Oligoarthritis is defined as arthritis affecting ≤4 joints during the first 6 months after disease onset, excluding children with enthesitis, psoriasis, and boys older than 6 years of age with HLA-B27. Oligoarthritis is sub divided into persistent and extended forms, based on the number of joints affected after the first 6 months; that is, 1-4 and >4 joints, respectively. RF + and RF -polyarthritis both affect ≥5 joints during the first 6 months of the disease; RF + disease is defined by two or more positive RF tests.
1 Table 1 summarizes the main clinical features associated with these four subtypes. Clinical differences imply distinct pathogenetic pathways for these subtypes, although current treatment approaches do not distinguish extended oligoarticular, RF + polyarticular and RF -polyarticular disease. Our understanding of the molecular basis of JIA subtypes is still unfolding, as discussed in this Review. Of note, the interpretation of some studies is confounded by changing schemes for JIA classification (see Box 1) and by analyses that combine subtypes to increase patient numbers.
Epidemiology
The reported incidence and prevalence of JIA vary widely, in part because JIA is a heterogeneous condition that is identified clinically without specific diag nostic tests. Available numbers are likely to underestimate the true incidence and prevalence of JIA because of under-diagnosis and because most studies are clinicbased rather than community-based. [8] [9] [10] In a comprehensive survey of data published as of 2002, Manners and Bower 11 concluded that the incidence of chronic arthritis of childhood ranges from 0.008 to 0.226 per 1,000 children, and that the prevalence ranges from 0.07 to 4.01 per 1,000 children worldwide. Recent US and Canadian studies report the incidence of JIA to be 0.041 to 0.061 per 1,000 children. [12] [13] [14] The best estimate of JIA prevalence in the US uses data recorded in the 2001-2004 national Ambulatory and national Hospital Ambulatory Medical Care Survey. Based on ICD-9-CM (International Classification of Diseases, ninth Revision, Clinical Modification) codes, approximately 294,000 US children aged 0-17 years (95% CI 188,000-400,000) are affected by the broadly defined "arthritis or other (similar) rheumatic conditions". 15 The major JIA subtypes vary by sex ratio and age at onset. 7 Girls are over-represented in groups of patients with oligoarticular JIA and polyarticular JIA. Age at onset for oligoarticular JIA peaks at 2-4 years; by contrast, age at onset of polyarticular JIA has a biphasic pattern, with peaks at 1-4 years and 6-12 years of age, with RF + disease contributing disproportionately to the second peak.
In north America and Europe, the relative frequencies of JIA subtypes are 10-30% RF -polyarticular, 5-10% RF + polyarticular, and 30-60% oligoarticular. 7 Studies of multi-ethnic communities from north America and from Europe suggest that, with the exception of RF + poly articular JIA, European ancestry is an important predisposing factor for JIA, especially for extended oligoarticular JIA and antinuclear-antibody (AnA)-associated JIA with uveitis. 16, 17 Conversely, patients of African American or native American descent are more likely to have RF + poly articular JIA than are children of European descent. 16, 18, 19 Studies from different geographic areas are difficult to compare, but it seems that in Asia the overall prevalence of JIA is lower than in Europe and north America, [20] [21] [22] and that ERA is particularly common. [20] [21] [22] [23] The prevalence of uveitis in oligoarticular and poly articular JIA subtypes is seeming ly highest in Scandinavia and lowest in East Asia and India. 24 Black South African patients, like African Americans, have a higher rate of RF + poly articular JIA and a lower rate of arthritis with uveitis compared to children of European descent. 25 Environmental influences are hypothesized to contribute to JIA pathogenesis, but specific agents have not been identified. In some reports, JIA is more prevalent in rural than urban settings. 26, 27 A single study conducted in Manitoba, Canada in 1975-1992 correlated cyclic increases in JIA incidence with the prevalence of mycoplasma infection.
14 Introduction of measles-mumpsrubella vaccination in Finland did not change the annual incidence of JIA, which argues against these infections as triggers of JIA. 28 An increasing incidence of JIA seems to be a worldwide trend, although the incidence of chronic pediatric arthritis in Rochester, Minnesota reportedly decreased from 0.150 cases per 1,000 children (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) to 0.078 per 1,000 children (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) . 29, 30 Further work is needed to confirm incidence trends and to identify factors that contribute to these patterns.
Overall, epidemiologic data corroborate clinical evidence that JIA subtypes represent discrete conditions. Data showing the influence of ethnicity on subtype
Key points
Epidemiologic, genetic and immunophenotypic evidence suggests that ■ oligoarticular (persistent and extended) and polyarticular (rheumatoid factor positive and negative) subtypes of juvenile idiopathic arthritis (JIA) are distinct etiopathological conditions
Reported incidence and prevalence of JIA vary widely, due partly to a lack ■ of specific diagnostic tests and to the rarity of community-based studies
Inherited susceptibility factors (both HLA and non-HLA) generally differ among ■ JIA subtypes, although the presence of some overlap in the latter suggests shared immunological pathways
Evidence supports a key role for T-cell-driven inflammation in oligoarticular ■ and polyarticular JIA and suggests a contribution of regulatory T cells to limiting disease in persistent oligoarticular JIA Dysregulation of cytokines, especially tumor necrosis factor, contribute to ■ oligoarticular and polyarticular JIA pathogenesis, and persistent cytokine abnormalities suggest that clinical remission is a state of compensated inflammation suscepti bility imply a role for genetics in JIA risk. To reveal more-detailed hypotheses on the pathogenesis of these subtypes, however, we must turn to studies of immunogenetics and immunophenotyping.
Pathogenesis
The presence of associations between HLA class II alleles and susceptibility to both oligoarticular and polyarticular JIA implicates CD4 + T cells in these subtypes. The specific HLA class II alleles associated, how ever, differ between the subtypes, which strongly suggests differences in molecular mechanisms. Indeed, as know ledge of CD4 + T cell subsets has grown, models of their involvement in oligoarticular and polyarticular JIA have been refined and support the idea that mechanistic differences exist. Available evidence also argues that antigen-driven autoimmunity is insufficient to explain all the features of oligoarticular and polyarticular JIA, 31 and implicate the involvement of both innate and adaptive immune responses. These issues are the focus of the rest of this Review.
genetic factors
Data from family and twin studies imply that susceptibility to JIA is inherited (reviewed elsewhere 32 ). For example, siblings of probands are 15-fold to 30-fold more likely than the general population to develop JIA. 33 All JIA subtypes are probably complex genetic traits, as they lack single-gene, Mendelian patterns of inheritance. Inherited risk factors for both disease suscepti bility and disease severity have been reported (Tables 2-4). The highly polymorphic HLA genes confer the strongest genetic effects in JIA, and, to a large extent, HLA allelic associations confirm clinically defined subtypes, including differences between persistent and extended oligo arthritis (Table 2 ). Initial findings on HLA genetic risk from association and linkage studies have been confirmed by genome-wide association studies (GwAS). 34, 35 HLA effects are observed within an age window of effect, REvIEWS and sex also influences the age at which some of the associated alleles have their effect. 36 Associations of HLA-A, HLA-B and HLA-DR with oligoarthritis are observed in girls but not boys, which raises the possibility of further heterogeneity in disease pathogenesis. 37 Shared HLA allelic associations imply a mechanistic relationship between extended oligo articular JIA and RF -poly articular JIA; however, this relation ship might be modified by the effects of differences in the associated HLA-DP alleles for these subtypes. Evidence suggests that different alleles confer susceptibility in different ethnic groups, as is the case for other MHC-associated diseases. [38] [39] [40] A caveat of interpreting genetic studies that use pre-ILAR classification criteria is that the patient groups are possibly heterogeneous; for example, the pauci articular subtype could include HLA-B27 + cases. 4 HLA class II has been estimated to account for ~20% of the sibling recurrence risk in oligoarticular and polyarticular JIA, which implies a role for non-HLA genes. 41 Approximately 100 non-HLA genes have been investigated for an association with JIA; however, many studies do not have the statistical power to detect moder ate or mild gene effects, particularly after stratification for JIA subtype. nevertheless, associations with some non-HLA genes have been confirmed (Table 3) . Some of these genes, such as PTPN22 and IL2RA (also known as 110 found CCP + in 60% of patients with oligoarticular JIA and 93% of those with polyarticular RF -JIA. **Patients refractory to this treatment can be administered other medications including a second anti-TNF agent, sulfasalazine, abatacept, rituximab, and leflunomide; no consensus exists on the order of introduction of these medications. ‡ ‡ Evidence suggests that extended oligoarticular JIA responds to a similar or perhaps greater extent than polyarticular JIA to methotrexate and anti-TNF agents, and comparably to abatacept (D. Lovell, personal communication). [111] [112] [113] [114] Abbreviations: CCP, cyclic citrullinated peptide; JIA, juvenile idiopathic arthritis; NA, not applicable; RF, rheumatoid factor; TNF, tumor necrosis factor.
Box 1 | Changes in juvenile arthritis classification
The current classification criteria for juvenile arthritis were developed by ILAR. These criteria were originally proposed in 1994 with revisions in 1997 and 2001.
The ILAR criteria for JIA replaced the ACR criteria for "juvenile rheumatoid arthritis" (1972, 1977 ) and the EULAR criteria for "juvenile chronic arthritis" EULAR criteria classify juvenile chronic arthritis as systemic, polyarticular (RF -) and pauciarticular, with polyarticular RF + classified as juvenile rheumatoid arthritis. Juvenile psoriatic arthritis and juvenile ankylosing spondylitis are included, but these two subtypes are not distinguished.
Abbreviations: ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; ILAR, International League of Associations for Rheumatology; JIA, juvenile idiopathic arthritis; RF, rheumatoid factor. REvIEWS CD25), are associated with multiple autoimmune diseases, 42 an observa tion that is consistent with the occurrence of various autoimmune disorders in families of JIA probands. 43 A 2009 GwAS found evidence of an association between VTCN1, a gene that encodes a negative regulator of T-cell-mediated responses, and JIA susceptibility. 35 Other candidate non-HLA genes are reportedly associated with risk of both oligo articular and polyarticular JIA subtypes, including genes that encode regulators of innate immunity such as the pro inflammatory cytokine MIF (macro phage migration inhibitory factor). By contrast, some studies reveal subtype-specific genetic effects. A GwAS found linkage of different chromosomal regions to oligo articular and polyarticular JIA subtypes, and distinction between early-onset and late-onset disease. 34 Another study found TNFAIP3 and C12orf30 variants associated with oligo articular JIA, and a STAT4 variant associated with polyarticular JIA. 44 The unique association between oligo articular JIA and IL2RA, 42 which is highly expressed on regulatory T cells, suggests the possibility that these cells have a particular role in this subtype. Some, but not all, cytokine gene associ ations distinguish the subtypes (Table 4 ). The a ssociation of a low-expression-level allele of osteo pontin with persistent oligoarticular JIA is consis tent with the morelimited disease observed in this subtype as compared with extended oligoarticular JIA, and further argues for a pathogenic distinction between the two forms of oligoarticular JIA. 45 Overall, observed genetic associations lend further support to the idea that the oligo articular and polyarticular subtypes have dif ferent etiologies, but also argue that certain immuno logical pathways, such as MIF-driven inflammation, could contribute to pathology across subtypes.
Immune-related factors

T cells and autoantigens
Associations of HLA alleles with polyarticular and oligoarticular JIA imply a role for adaptive immunity, and especially T cells, in the pathogenesis of these subtypes. 
REvIEWS
A number of lines of cellular evidence support this possi bility, the oldest being the presence of T-cell and plasma-cell infiltrates in affected joints. However, some differences exist in T-cell phenotype in oligo articular compared with polyarticular JIA, providing clues to subtype-specific mechanisms.
One aspect of T-cell biology that might have a role in JIA is impaired thymic function. Accelerated loss and premature aging of naive CD4 + T cells, the latter detected as telomeric erosion, have been reported in oligo articular and polyarticular JIA, independent of treatment. 46 A study of all JIA subtypes, however, found no difference in thymic function between patients with JIA and controls. 47 Difficulty discriminating between recent thymic emigrants and long-lived peripheral naive T cells could be one of the reasons for these discordant results; markers that better distinguish these two T-cell populations may clarify the role of thymic function in JIA. 48 Evidence of T-cell activation is a feature of patients with oligoarticular and polyarticular JIA, although critical or initiating antigens have not been determined. Activated CD4 + T cells are found at increased levels in circulation 49 and in the synovium in children with JIA as compared with healthy, age-matched children, with the CD4:CD8 ratio in joint tissue being higher in polyarticular JIA compared with oligoarticular JIA. 50 Selected CD4 + clones not abundant in circulation are expanded within the joints in persistent and extended oligo articular and polyarticular patients, 51 ,52 but precipitating antigens for these expansions have not been identified. Evidence for autoreactivity of circulating T cells includes responses to the joint-related proteins aggrecan and fibrillin, the latter primarily in patients with poly articular JIA.
53
Several heat shock proteins (HSPs) are also potential autoantigens in JIA. Highly conserved across species, HSPs are produced in response to cell stress. Circulating T cells from oligo articular and polyarticular JIA patients, but not controls, react to human HSP60.
54,55 Human HSP70 is expressed on synovial cell membranes in all JIA subtypes and might act as an autoantigen. Alternatively, ligation of HSP70 and autoantigens may promote au toantigen pr ocessing and presentation. 56 Autoreactive CD8 + T cells have also been implicated in the pathogenesis of polyarticular and oligoarticular JIA. Activated CD8 + T cells are found in circulation 49 and in the synovium, 50 with a suggestion of higher levels of activation in oligoarticular JIA compared with the poly articular subtype. Consistent with redistribution of these cells to the joints, absolute numbers of circulating CD8 + CD45RA + (naive) T cells are decreased in oligoarticular JIA in comparison with healthy, age-matched controls, even after clinical remission. 57 Several studies have addressed potential autoantigenic specificities of CD8 + T cells. Peptides from self-HLA proteins (HLA DRB1*1101, DRB1*0801 and DRP1*0201) with ho mology to Epstein-Barr-virus-derived peptides trigger cytotoxicity and proinflammatory cytokine produc tion from peripheral blood CD8 + T cells of patients with oligo articular JIA. 58 In a study of patients primarily with polyarticular JIA, peripheral blood 10 (also known as IP-10), and the ligands for CCR5, CCL3 (also known as MIP-1α) and CCL5 (also known as RAnTES).
62-64 One model that accounts for these observations is that CCR7 + CXCR3 + cells might be recruited directly to the synovium, where they may become effector cells that downregulate CCR7 and upregulate CCR5; CCR5, in turn, may be the main receptor used for migration within the synovial tissue. 62 Furthermore, CCL5 might enhance T-cell production of IFn-γ. 65 while effector T cells in the synovial fluid of both polyarticular and oligo articular JIA patients express higher IFnγ:IL-4 ratios than their peripheral blood counterparts, 66 IL-4 is more prominent in the synovial compartments of patients with oligo articular JIA than in those with polyarticular JIA. This pattern is consistent with the more-limited arthritis associ ated with this subtype, and suggests a deviation from T H 1 towards T H 2-biased phenotypes. 67 In poly articular JIA, even peripheral blood mononuclear cells have elevated levels of genes induced by IFn-γ.
68
A new paradigm suggests that a key inflammatory CD4 + T-cell subset produces IL-17, and that the development of this subset is negatively regulated by T H 1 cells.
69
The inflamed joints of all JIA subtypes are enriched with IL-17-producing T cells, and high levels of IL-17, in excess of serum levels, are detected in synovial fluid in polyarticular JIA.
70,71 IL-17 potently induces synovio cyte production of IL-6, matrix metalloproteinases (MMPs) 1 and 3, and IL-8 (which is chemotactic for neutrophils), all of which have been implicated in joint damage. 
CTLA4
+ T cells). 77 T-cell reactivity to human HSP60 is associated with remission in oligoarticular JIA; the protective mechanism seems to involve induction of IL-10 production by CD30 + T cells. 78, 79 In summary, it seems that proinflammatory T cells are recruited to the joint in both oligoarticular and polyarticular JIA, where they drive inflammation; however, this activity is perhaps better controlled by regula tory mechanisms in persistent oligoarticular disease than in extended oligoarticular disease.
Dendritic cells and B cells
T-cell activation is dependent on antigen-presenting cells, the most potent of which are dendritic cells (DCs). DCs are thought to participate in the initiation, maintenance and/or regulation of inflammation in JIA, although few studies provide direct evidence for this. In oligoarticular and polyarticular JIA patients, conventional DCs (cDCs) and IFn-α-producing DCs (plasmacytoid dendritic cells [pDCs] ) are enriched in synovial fluid compared with the circulation. 80 One study found synovial fluid DCs to be more numerous in polyarticular JIA than in oligo articular JIA, and found lower numbers of circulat ing DCs to be associated with a reduced response to treatment. 81 within synovial tissue, pDCs are found in lymphoid follicle-like structures, while cDCs are mostly found at the lining and sublining layers, which suggests that DC subtypes mediate distinct processes in the joint. 80 cDCs expressing RAnK ( receptor-activator for nuclear factor κB; also known as tumor necrosis factor receptor superfamily, member 11A) are found in the joints of patients with oligo articular and polyarticular JIA. 82 RAnK-mediated activation of DCs leads to increased survival of these REvIEWS cells and production of inflammatory cytokines. 83 Further investigation of DC migration to and function in the joint micro environment is warranted.
The major autoantibody specificities found in JIA (AnA, RF, and anti-cyclic citrullinated peptide [CCP] antibodies) have not been directly implicated in disease development, although they serve as biomarkers of clinical subsets. AnA is associated with uveitis in oligoarticular JIA, and IgM RF and/or anti-CCP antibodies are associated with erosive disease in polyarticular JIA. 84 Ravelli et al. 17 + B cells, a minor B-cell subset, are observed in oligoarticular and polyarticular JIA (as well as rheumatoid arthritis). 49, 86 CD5 + B cells typically produce antibodies against bacterial wall components, but are also a source of low-affinity multi-specific antibodies. whether CD5 + B cells produce disease-related autoantibodies in JIA is not known. Given the efficacy of rituximab for rheumatoid arthritis, and the renewed interest in B cells as pathogenic effectors, 87 more studies of B cells in JIA are likely to be forthcoming.
Monocytes and proinflammatory cytokines
Elevated levels of proinflammatory cytokines are found in the circulation and synovial compartments in patients with JIA. Serum levels of tumor necrosis factor (TnF) are elevated in oligoarticular and polyarticular JIA, 88 as are serum levels of IL-6, but the highest IL-6 levels are found in sJIA. [88] [89] [90] [91] Circulating IL-1β can be elevated in oligo articular and polyarticular JIA, 90 although this finding is not consistent. 88 In active arthritis, levels of pro inflammatory cytokines are generally higher in syno vial fluid than in circulation, most likely due to local produc tion. For example, complexes of IL-6 and a soluble form of the IL-6 receptor, which bind to surface gp130 on chondrocytes and fibroblasts, are thought to trigger further IL-6 production by these cells. 92 On the basis of subtype-specific responses to anticytokine therapies, particular cytokines seem to be primary effectors in JIA subtypes. For polyarticular JIA and extended oligoarticular JIA, blockade of TnF has been efficacious, suggesting a crucial role for TnF in these subsets. 93 TnF is inhibited endogenously by its soluble receptors, and its damaging effects in polyarticular JIA might be attributable to a reduced ratio of soluble TnF receptor to TnF. 94 A study of transcriptional profiles of peripheral blood mononuclear cells from patients with newly diagnosed polyarticular JIA identified a subgroup with elevated expression of monocyte-associated genes, including genes that encode the monocyte markers CD64 and CD14. This subgroup included primarily RF + individuals, which raises the possi bility that monocyte-driven inflammation is of particular importance in these patients. 85 A key observation in all JIA subtypes is that, while levels of inflammatory cytokines are higher during active disease, levels are abnormal during clinical remission, 91 which suggests that remission represents a state of compensated inflammation that is overwhelmed during disease flare.
Innate immune dysfunction in JIA subtypes
Although HLA associations and other immunophenotypic data argue strongly for dysregulated adaptive immune responses in oligoarticular and polyarticular JIA, recent evidence also suggests an important role for innate immune activation in these subtypes. Levels of the proteins S100A8 and S100A9 (or their heterodimeric form S100A8/S100A9) and S100A12, which are secreted products of activated neutrophils and monocytes, are increased in the serum in oligoarticular and poly articular JIA, and their concentration correlates positively with the degree of inflammation. 95 These molecules belong to the damage-associated molecular pattern proteins (DAMPs), which act as endogenous danger signals and activate immune cells and vascular endothelium. 96 Direct cytotoxic effects of the S100 proteins may also con tribute to tissue damage. 96 In patients with polyarticular and oligo articular JIA, protein S100A8/S100A9 levels correlate positively with disease activity and increase before onset of clinical flare, which suggests that they act early in the inflammatory cascade associated with periods of disease activity. 97 Levels of protein S100A12 also correlate positively with, and may be early mediators of, disease activity for oligoarticular JIA and polyarticular JIA. 98 Although neutrophils are the most abundant cell popula tion in JIA synovial fluid, few studies have concentrated on this cell type. Gene expression analysis suggests neutro phil abnormalities exist in polyarticular JIA patients. Expression of more than 700 genes, including IFn-γ-related and IL-8-related genes, differs in patients with polyarticular JIA compared with healthy controls, and some differences persist after response to therapy 99 or even during drug-free clinical remission. 100 The nADPH cycle is dysregulated in neutrophils from patients with active and inactive RF -polyarticular JIA, which suggests an intrinsic neutrophil defect in these patients. 31 Synovial inflammation and tissue damage within each of the oligoarticular and polyarticular JIA subtypes, a subset of patients suffer significant joint damage: the RF + /anti-CCP + group in polyarticular JIA, and patients with the extended oligoarticular phenotype of oligoarticular JIA. 101, 102 The processes media ting joint damage seem to be shared across JIA subtypes. The hallmarks of inflamed synovium are increased vasculariza tion and endothelial activation. Factors such REvIEWS as vascular endothelial growth factor, osteopontin and reactive oxygen species induce the formation of new vascu lature, thereby facilitating an influx of inflammatory cells. Inflammatory cells subsequently drive the activation of RAnK-expressing osteoclasts and proteases, especially MMPs, which increases the ratio of MMPs to their in hibitors (tissue inhibitor of metalloproteinases [TIMPs]). Cartilage and bone destruction ensues, enhanced by a reduced capacity for tissue repair (for example, due to increased osteoblast apoptosis) in the setting of inflammation.
103-106
Conclusions
Using clinical phenotypes, epidemiologic data and HLA immunogenetics as a foundation, the ILAR criteria for JIA subtypes were defined by consensus conference, and have been used globally for clinical and translational research and for the development of practice patterns and treatment algorithms. Implied in this subtyping is the hypo thesis that different forms of chronic arthritis in childhood arise through distinct etio pathological pathways. Evidence reviewed here lends support to the general idea of differences in pathogenesis between subtypes. However, some results suggest areas of mechanis tic overlap, even between oligoarticular and poly articular JIA, for example the contributions of T H 1 cells, MIF-driven innate immune activation and S100 proteins to joint inflammation. Other results imply further hetero geneity than is captured in the current classification scheme. Based on epidemiologic and new molecular data, the AnA + arthritis subgroup may prove to be mechanistically distinct. The sub categories of persis tent and extended oligoarticular JIA may eventu ally be recog nized as independent subtypes, with a defining role for CD4 + CD25 + T REG cells in controlling inflammation in the persistent form. However, much remains to be done to generate full molecular pictures of these conditions. Fortunately, the collaborative research effort that is probably necessary to achieve this goal is starting: an international team of investigators will soon begin working towards developing a bio logical classification system for JIA-ILAR II (R. Yeung, personal communication).
Review criteria
We searched PubMed for original papers that focused on juvenile arthritis and epidemiology, genetics, and pathogenesis. Search terms used, alone or in combination, were "juvenile arthritis", "epidemiology", "gene/genetic", "pathogenesis", "T/B cells", "antigen", "autoantibody", "cytokine", "monocyte/macrophage", "neutrophil", "NK cells", "dendritic cells", "apoptosis", "adhesion molecules", "chemokine", "matrix metalloproteinase", "cartilage", and "regulation". 
